SYNGAP1 is a rare genetic condition that affects the central nervous system, leading to intellectual disability, developmental delays, and epilepsy. Despite the profound impact of SYNGAP1 (ICD-10: F78.A1) on those affected and their families, there is still much to be learned about this condition and the best ways to treat it. That's where the SynGAP Research Fund (SRF) comes in.
SRF is a patient-led charity that raises money from families and their networks to fund research into SYNGAP1. With a mission to accelerate therapeutic development for this condition, SRF has already committed over $3.7 million to research to date. This makes SRF a great choice for donors who want to make a real difference in the lives of those affected by SYNGAP1.
One of the unique benefits of SRF is that 100% of donated funds go directly to research. The founders cover all overhead and operating expenses, so donors can be confident that their contributions will have maximum impact.
Researchers interested in studying SYNGAP1 are encouraged to apply for grants from SRF. The Fund accepts grant proposals twice a year, on March 1st and September 1st, and all details can be found here.
The SRF board has identified a number of current priority areas for research in 2023, including:
By joining the growing group of excellent scientists and clinicians working towards a cure for SYNGAP1, researchers can make a real impact in the lives of those affected by this condition. If you're a researcher interested in making a difference, we encourage you to apply for a grant from SRF today. With the support of dedicated donors and dedicated researchers, we can work together to find better treatments and a cure for SYNGAP1.